- Home
- CCCC vs CDXS Comparison
CCCC vs CDXS Comparison
Compare CCCC & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCCC
- CDXS
- Stock Information
- Founded
- CCCC 2015
- CDXS 2002
- Country
- CCCC United States
- CDXS United States
- Employees
- CCCC N/A
- CDXS N/A
- Industry
- CCCC Biotechnology: Pharmaceutical Preparations
- CDXS Major Chemicals
- Sector
- CCCC Health Care
- CDXS Industrials
- Exchange
- CCCC Nasdaq
- CDXS Nasdaq
- Market Cap
- CCCC 396.0M
- CDXS 406.9M
- IPO Year
- CCCC 2020
- CDXS 2010
- Fundamental
- Price
- CCCC $3.93
- CDXS $5.04
- Analyst Decision
- CCCC Buy
- CDXS Buy
- Analyst Count
- CCCC 6
- CDXS 2
- Target Price
- CCCC $10.67
- CDXS $11.00
- AVG Volume (30 Days)
- CCCC 2.0M
- CDXS 739.7K
- Earning Date
- CCCC 02-20-2025
- CDXS 02-26-2025
- Dividend Yield
- CCCC N/A
- CDXS N/A
- EPS Growth
- CCCC N/A
- CDXS N/A
- EPS
- CCCC N/A
- CDXS N/A
- Revenue
- CCCC $33,668,000.00
- CDXS $64,446,000.00
- Revenue This Year
- CCCC $75.79
- CDXS N/A
- Revenue Next Year
- CCCC N/A
- CDXS $2.02
- P/E Ratio
- CCCC N/A
- CDXS N/A
- Revenue Growth
- CCCC 65.45
- CDXS N/A
- 52 Week Low
- CCCC $3.38
- CDXS $2.53
- 52 Week High
- CCCC $11.88
- CDXS $6.08
- Technical
- Relative Strength Index (RSI)
- CCCC 48.86
- CDXS 53.86
- Support Level
- CCCC $3.79
- CDXS $4.24
- Resistance Level
- CCCC $4.03
- CDXS $5.43
- Average True Range (ATR)
- CCCC 0.26
- CDXS 0.32
- MACD
- CCCC 0.05
- CDXS -0.00
- Stochastic Oscillator
- CCCC 62.50
- CDXS 62.99
About CCCC C4 Therapeutics Inc.
C4 Therapeutics Inc is a biopharmaceutical company advancing targeted protein degradation science to develop a new generation of small-molecular medicines to transform how the disease is treated. Its TORPEDO platform enables the discovery of a new class of targeted investigational small-molecule medicines called protein degraders.
About CDXS Codexis Inc.
Codexis Inc is involved in the business of providing enzyme optimization services, commercialization of proteins, and developing biocatalyst products, leveraging its proprietary CodeEvolver directed evolution technology platform. The firm's products and services include Biocatalysts and Enzymes. The company generates majority of its revenue through product sales and also licenses its technology platform CodeEvolver to pharmaceutical companies enabling them to use this technology, in-house, to engineer enzymes for their own businesses. Geographically, it derives revenue from the United States, Ireland, Switzerland, China and other markets.